These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33935967)

  • 21. Interleukin-3 plays dual roles in osteoclastogenesis by promoting the development of osteoclast progenitors but inhibiting the osteoclastogenic process.
    Hong H; Shi Z; Qiao P; Li H; McCoy EM; Mao P; Xu H; Feng X; Wang S
    Biochem Biophys Res Commun; 2013 Nov; 440(4):545-50. PubMed ID: 24103757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-17 promotes osteoclastogenesis and periodontal damage via autophagy in vitro and in vivo.
    Zhong J; Wang Z; Yuan W; Shen Y; Chen L
    Int Immunopharmacol; 2022 Jun; 107():108631. PubMed ID: 35219162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSF.
    Zauli G; Rimondi E; Nicolin V; Melloni E; Celeghini C; Secchiero P
    Blood; 2004 Oct; 104(7):2044-50. PubMed ID: 15213096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Potential mechanism of transcription factor peroxisome proliferator-activated receptor-gamma coactivator-1 beta on promoting osteoclastogenesis].
    Wang JW; Ma JD; Jing J; Wei XN; Li QH; Liang JJ; Zheng DH; Dai L
    Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(46):3638-3644. PubMed ID: 31826586
    [No Abstract]   [Full Text] [Related]  

  • 27. Glaucocalyxin A suppresses osteoclastogenesis induced by RANKL and osteoporosis induced by ovariectomy by inhibiting the NF-κB and Akt pathways.
    Zhu M; Shan J; Xu H; Xia G; Xu Q; Quan K; Liu X; Dai M
    J Ethnopharmacol; 2021 Aug; 276():114176. PubMed ID: 33933570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL production in rheumatoid arthritis.
    Kim HR; Kim KW; Kim BM; Lee KA; Lee SH
    Korean J Intern Med; 2019 Jan; 34(1):210-219. PubMed ID: 28286938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-4 released from human gingival fibroblasts reduces osteoclastogenesis.
    Ujiie Y; Karakida T; Yamakoshi Y; Ohshima T; Gomi K; Oida S
    Arch Oral Biol; 2016 Dec; 72():187-193. PubMed ID: 27608363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
    Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
    Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions.
    Shukla P; Mansoori MN; Singh D
    Bone; 2018 May; 110():84-95. PubMed ID: 29414600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells.
    Kitami S; Tanaka H; Kawato T; Tanabe N; Katono-Tani T; Zhang F; Suzuki N; Yonehara Y; Maeno M
    Biochimie; 2010 Apr; 92(4):398-404. PubMed ID: 20045440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psoralen and Bakuchiol Ameliorate M-CSF Plus RANKL-Induced Osteoclast Differentiation and Bone Resorption Via Inhibition of AKT and AP-1 Pathways in Vitro.
    Chai L; Zhou K; Wang S; Zhang H; Fan N; Li J; Tan X; Hu L; Fan X
    Cell Physiol Biochem; 2018; 48(5):2123-2133. PubMed ID: 30110702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis.
    Lee KA; Kim KW; Kim BM; Won JY; Min HK; Lee DW; Kim HR; Lee SH
    Arthritis Res Ther; 2019 Dec; 21(1):283. PubMed ID: 31831038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of lipopolysaccharide on osteoclasts formation and bone resorption function and its mechanism].
    Zeng L; Xu Y; Xing G
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2018 May; 32(5):568-574. PubMed ID: 29806344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melittin inhibits osteoclast formation through the downregulation of the RANKL-RANK signaling pathway and the inhibition of interleukin-1β in murine macrophages.
    Choe JY; Kim SK
    Int J Mol Med; 2017 Mar; 39(3):539-548. PubMed ID: 28204822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.
    Chen C; Qin Y; Fang JP; Ni XY; Yao J; Wang HY; Ding K
    Acta Pharmacol Sin; 2015 Sep; 36(9):1053-64. PubMed ID: 26299951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans.
    Yu H; Herbert BA; Valerio M; Yarborough L; Hsu LC; Argraves KM
    Lipids Health Dis; 2015 Jul; 14():66. PubMed ID: 26138336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IL-35 and RANKL Synergistically Induce Osteoclastogenesis in RAW264 Mouse Monocytic Cells.
    Kamiya Y; Kikuchi T; Goto H; Okabe I; Takayanagi Y; Suzuki Y; Sawada N; Okabe T; Suzuki Y; Kondo S; Hayashi JI; Mitani A
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32197293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
    Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
    Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.